CXCL10 and ductal breast carcinoma in situ: In invasive carcinoma, CXCL10 expression was more commonly observed compared to DCIS with 81 cases (21.8%) of CXCL10-positive tumors among 372 cases of invasive carcinomas (p < 0.001).